beta

RDHL

Redhill Biopharma Ltd.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

redhill biopharma is a biopharmaceutical company focused primarily on development of late clinical-stage new, improved and patented formulations of existing drugs. redhill has an experienced management team, board of directors and advisory board based in israel, the us, canada and europe, with successful track record at big and small pharma of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise

Market Cap: 497 Thousand

Primary Exchange: NASDAQ

Website: https://www.redhillbio.com/

Shares Outstanding: 882 Thousand

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.24453398747323601

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 1758 trading days

From: 2015-06-16 To: 2024-03-07

Lowest Point:

RedHill nabs U.S. patent covering RHB-104 and RHB-204

via: SeekingAlpha at 2019-06-10 11:21:52:000

The USPTO has issued a Notice of Allowance to RedHill Biopharma ( RDHL -0.8% ) for a new patent covering RHB-104 for Crohn's disease and RHB-204 for Mycobacterium avium complex disease. Once issued, the patent should be effective until at least 2029. More news on: RedHill B… read more...

RedHill nabs U.S. patent covering RHB-104 and RHB-204

via: SeekingAlpha at 2019-06-10 11:21:52:000

The USPTO has issued a Notice of Allowance to RedHill Biopharma ( RDHL -0.8% ) for a new patent covering RHB-104 for Crohn's disease and RHB-204 for Mycobacterium avium complex disease. Once issued, the patent should be effective until at least 2029. More news on: RedHill B… read more...

RedHill nabs U.S. patent covering RHB-104 and RHB-204

via: SeekingAlpha at 2019-06-10 11:21:52:000

The USPTO has issued a Notice of Allowance to RedHill Biopharma ( RDHL -0.8% ) for a new patent covering RHB-104 for Crohn's disease and RHB-204 for Mycobacterium avium complex disease. Once issued, the patent should be effective until at least 2029. More news on: RedHill B… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud